Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of November 2023. The report addresses a corporate governance event regarding the Extraordinary General Meeting of Shareholders originally scheduled for November 16, 2023.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural announcement and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the adjournment of the Extraordinary General Meeting of Shareholders due to a lack of required legal quorum. Consequently, the meeting has been rescheduled.
Guidance, Outlook, and Management Commentary
- Meeting Reschedule: The Board of Directors approved postponing the meeting to November 29, 2023, at 3:00 p.m. Israel time.
- Location: The meeting will be held at the Company's offices at 21 Ha'arba'a Street, Tel-Aviv, Israel.
- Voting Deadline: All votes submitted to The Bank of New York Mellon must be received by 12:00 p.m. EST on November 24, 2023.
- Registration Statements: The filing is incorporated by reference into multiple Registration Statements on Form S-8 and Form F-3 filed between 2013 and 2023.
Key Facts for Investor Verification
- Verify the new meeting date of November 29, 2023, and the specific agenda items to be voted upon.
- Confirm the voting deadline of November 24, 2023, at 12:00 p.m. EST for American Depositary Shares.
- Review the original proxy materials to understand the proposals that failed to achieve a quorum.
- Check subsequent filings for the outcome of the rescheduled meeting.